NCT06819293RecruitingPhase 1
IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
A Phase I, Open Label, Single Center Study Evaluating the Safety and Efficacy of IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 14 Apr 2026
Brief summary (registry, in English)
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 5 Feb 2025
- Start date
- 6 Dec 2024
- Primary completion date
- 7 Dec 2027
- Lead sponsor
- Grit Biotechnology
- Diseases
- Kidney cancer
- NCT number
- NCT06819293
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 12
- From 6 Dec 2024 to the primary completion date, 7 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have experienced myocardial infarction or unstable angina within the 6 months prior to screening
- Pleural effusion requiring drainage for symptom management within 28 days prior to screening
Other illness
- CNS dysfunction with clinical significance. For example, seizures, cerebral ischemia/hemorrhage, dementia, cerebellar diseases, cerebral edema, reversible posterior encephalopathy syndrome, or any autoimmune disease involving the CNS.
- Any form of primary and acquired immunodeficiency (such as severe combined immunodeficiency). Known human immunodeficiency virus (HIV) positive subjects
Who the study is looking for
- Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;
- Age ≥18 years old;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- Expected survival time of ≥ 3 months;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.